Breaking News, Collaborations & Alliances

MicrofluidX, Immatics Partner on Automated End-to-End Bioprocessing for TCR-T Therapies

Joint research project aims to increase efficiency and reduce cost of manufacture through precision process control.

MicrofluidX, a provider of next- generation bioreactors for cell biology research and cell therapy manufacturing, entered a joint research project with Immatics, a developer of T cell receptor (TCR)-based immunotherapies, to combine Immatics’ manufacturing of TCR-T cells with MicrofluidX’s new platform, the Cyto Engine. MicrofluidX and Immatics will collaborate to investigate more efficient and cost-effective manufacturing solutions for Cell and Gene Therapies. By utilizing the Cyto Engine’s ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters